Prognosis value of plasma S100B protein levels after subarachnoid aneurysmal hemorrhage.

Department of Anesthesiology and Critical Care, Centre Hospitalo-Universitaire Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie, Paris, France.
Anesthesiology (Impact Factor: 6.17). 05/2006; 104(4):658-66. DOI: 10.1097/00000542-200604000-00008
Source: PubMed

ABSTRACT S100B has been described as a biologic marker of neuronal damage. The purpose of this study was to assess its prognostic value in patients with subarachnoid aneurysmal hemorrhage.
Seventy-four patients (32 men and 42 women; age, 48 +/- 11 yr) admitted within 48 h after subarachnoid hemorrhage onset and treated by surgical clipping or coiling within 2 days after admission were included. World Federation of Neurological Surgeons, Fisher, and Glasgow outcome scores at intensive care unit discharge and at 6 months were evaluated. Blood concentrations of S100B were determined at admission and daily up to day 8.
The time course of S100B was increased in patients with high World Federation of Neurological Surgeons and Fisher scores. Patients who underwent surgical clipping had an S100B time course longer than that of those who underwent coiling. This difference remained true after stratification for World Federation of Neurological Surgeons and Fisher scores. The threshold of mean daily value of S100B predicting a poor outcome at 6 months was 0.4 microg/l (sensitivity = 0.50 [95% confidence interval (CI), 0.29-0.71], specificity = 0.87[corrected] [95% CI, 0.76-0.95]). In multivariate analysis, high World Federation of Neurological Surgeons score (odds ratio = 9.5 [95% CI, 3.1-29.4]), mean daily S100B value above 0.4 microg/l (odds ratio = 7.3 [95% CI, 2.3-23.6]), and age (odds ratio = 1.08 per year [95% CI, 1.01-1.15]) were independent predictors of a poor 6-month outcome (Glasgow outcome score 1-3).
Mean daily value of S100B assessed during the first 8 days is a prognostic tool complementary to initial clinical evaluation in subarachnoid hemorrhage patients.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Subarachnoid hemorrhage (SAH) accounts for 5% of strokes with a high rate of death and complications. It occurs in a fairly young, often hypertensive and smoking, population. Patients usually present with sudden headache. Clinical evaluation uses a prognostic scale including level of consciousness and motor deficit on admission. CT brain scanning evaluates the initial blood amount, predictive of the occurrence cerebral vasospasm. After referral to a multidisciplinary center with neurovascular expertise, angiography detects the ruptured aneurysm, the cause of SAH in 85% of cases. Since rebleeding is an imminent danger, occlusion of the aneurysm should be performed on an emergency basis within the first 72 h, either by endovascular or microsurgical approach. Medical management includes early detection of hydrocephalus, maintenance of normovolemia and oral calcium antagonists. Cerebral vasospasm is a devastating complication inducing death and functional impairment related to delayed cerebral ischemia. Since pathophysiological knowledge is incomplete, prevention strategies remain limited. Treatment of cerebral vasospasm associates maintenance of cerebral perfusion and more invasive techniques such as chemical or mechanical angioplasty.
    Réanimation 10/2007; 16(6):463–471.
  • [Show abstract] [Hide abstract]
    ABSTRACT: For patients presenting with acute brain injury (such as traumatic brain injury, subarachnoid haemorrhage and stroke), the diagnosis and identification of intracerebral lesions and evaluation of the severity, prognosis and treatment efficacy can be challenging. The complexity and heterogeneity of lesions after brain injury are most probably responsible for this difficulty. Patients with apparently comparable brain lesions on imaging may have different neurological outcomes or responses to therapy. In recent years, plasmatic and cerebrospinal fluid biomarkers have emerged as possible tools to distinguish between the different pathophysiological processes. This review aims to summarise the plasmatic and cerebrospinal fluid biomarkers evaluated in subarachnoid haemorrhage, traumatic brain injury and stroke, and to clarify their related interests and limits for diagnosis and prognosis. For subarachnoid haemorrhage, particular interest has been focused on the biomarkers used to predict vasospasm and cerebral ischaemia. The efficacy of biomarkers in predicting the severity and outcome of traumatic brain injury has been stressed. The very early diagnostic performance of biomarkers and their ability to discriminate ischaemic from haemorrhagic stroke were studied.
    Critical care (London, England) 04/2014; 18(2):220. · 5.04 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Context: Subarachnoid hemorrhage (SAH) has a high fatality rate and many suffer from delayed neurological deficits. Biomarkers may aid in the identification of high-risk patients, guide treatment/management and improve outcome. Objective: The aim of this review was to summarize biomarkers of SAH associated with outcome. Methods: An electronic database query was completed, including an additional review of reference lists to include all potential human studies. Results: A total of 298 articles were identified; 112 were reviewed; 55 studies were included. Conclusion: This review details biomarkers of SAH that correlate with outcome. It provides the basis for research investigating their possible translation into the management of SAH patients.
    Biomarkers 02/2014; · 2.52 Impact Factor


Available from
May 19, 2014